TriangleDISEASE & TREATMENT SETTING
Hodgkin Lymphoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Hodgkin Lymphoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Hodgkin Lymphoma; Hodgkin Lymphoma Treatment During Pregnancy. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
12 more-specific settings
Adcetris: Hodgkin Lymphoma after prior therapy →Opdivo: recurrent Hodgkin Lymphoma →Opdivo: recurrent Hodgkin Lymphoma after prior therapy →Lomustine: Hodgkin's Lymphoma after prior therapy →CARMUSTINE: metastatic Hodgkin's Lymphoma →Gleostine: Hodgkin's Lymphoma after prior therapy →KEYTRUDA: refractory Hodgkin Lymphoma →Gleostine: Hodgkin's Lymphoma after prior therapy →Lomustine: Hodgkin's Lymphoma after prior therapy →ADCETRIS: recurrent Hodgkin Lymphoma after prior therapy →advanced Hodgkin Lymphoma →recurrent Hodgkin Lymphoma →
Study evidence for this setting
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Stem Cell Transplant for Hematological Malignancy
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
Indication-specific source history
2011-08-19 · Adcetris (brentuximab vedotin) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- fda-6a78295c5118c4ae
- event date
- 2011-08-19
- event kind
- accelerated-approval
- drug or regimen
- Adcetris (brentuximab vedotin)
- source indication text
- Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or after failure of at least 2 multi-agent chemotherapy regimens in patients who are not ASCT candidates
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9338ee555ed6e6a0a77f
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2015-08-17 · Adcetris (brentuximab vedotin) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- fda-0e3fc2ff65c4b184
- event date
- 2015-08-17
- event kind
- traditional-approval
- drug or regimen
- Adcetris (brentuximab vedotin)
- source indication text
- Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or after failure of at least 2 multi-agent chemotherapy regimens in patients who are not ASCT candidates
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9338ee555ed6e6a0a77f
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2016-05-17 · Opdivo (nivolumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- fda-df2ce15cd5692433
- event date
- 2016-05-17
- event kind
- accelerated-approval
- drug or regimen
- Opdivo (nivolumab)
- source indication text
- For the treatment of classical Hodgkin Lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-ba482fe42a99a5183f74
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-03-14 · Keytruda (pembrolizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- fda-ac13eb2b7c2199b0
- event date
- 2017-03-14
- event kind
- accelerated-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- Adult and pediatric patients with refractory classical Hodgkin Lymphoma or who have relapsed after 3 or more prior lines of therapy
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-21622ee7f20537f91824
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-04-25 · Opdivo (nivolumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- fda-e120d163d666f737
- event date
- 2017-04-25
- event kind
- accelerated-approval
- drug or regimen
- Opdivo (nivolumab)
- source indication text
- Treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after:Autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, Or3 or more lines of systemic therapy that includes autologous HSCT
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-843c91b9b3deb5777e25
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-10-14 · Keytruda (pembrolizumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- fda-98982fb64dee93e8
- event date
- 2020-10-14
- event kind
- traditional-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- Adult and pediatric patients with refractory classical Hodgkin Lymphoma or who have relapsed after 3 or more prior lines of therapy
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-21622ee7f20537f91824
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-03-20 · Opdivo (nivolumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- fda-72c696623937855d
- event date
- 2026-03-20
- event kind
- traditional-approval
- drug or regimen
- Opdivo (nivolumab)
- source indication text
- For the treatment of classical Hodgkin Lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-ba482fe42a99a5183f74
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-03-20 · Opdivo (nivolumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- fda-cbaa884e620c3a8e
- event date
- 2026-03-20
- event kind
- traditional-approval
- drug or regimen
- Opdivo (nivolumab)
- source indication text
- Treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after:Autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, Or3 or more lines of systemic therapy that includes autologous HSCT
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-843c91b9b3deb5777e25
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-03-20 · nivolumab with chemotherapy · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- event id
- notice-ff80d3e1bc7f067c
- event date
- 2026-03-20
- event kind
- approval-notification
- drug or regimen
- nivolumab with chemotherapy
- source indication text
- FDA approved nivolumab with doxorubicin, vinblastine, and dacarbazine for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma . The FDA also granted traditional approval to nivolumab for the following indications in adults with relapsed or refractory cHL:
- match phrase
- hodgkin lymphoma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-491ef4b41b9bb54f
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- binding id
- ncit-C7702
- source collection
- ncit-concept
- source key
- C7702
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- binding id
- ncit-C7714
- source collection
- ncit-concept
- source key
- C7714
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-hodgkin-lymphoma
- binding id
- ncit-C9357
- source collection
- ncit-concept
- source key
- C9357
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice